Serum Urate Goals Tied to Lower CV Risk - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Serum Urate Goals Tied to Lower CV Risk

Patients with gout who reached serum urate targets had modestly higher 5-year cardiovascular event-free survival, with associations strongest among high-risk patients

  • By

  • Andrea Surnit

  • May 11, 2026

  • 4 min

Share

  • 1

    Achieving serum urate targets with urate-lowering therapy reduces the 5-year risk of major adverse cardiovascular events in gout patients.

  • 2

    In a study of 109,504 adults, those who reached urate levels below 6 mg/dL had a hazard ratio of 0.91 for cardiovascular events.

  • 3

    Patients achieving urate levels below 5 mg/dL showed an even stronger association, with a hazard ratio of 0.77 and a 3 percentage point survival difference.

  • 4

    The study highlights a potential link between gout flares, systemic inflammation, and cardiovascular risk, rather than urate lowering alone.

  • 5

    Despite adjustments, residual confounding may affect results, and fewer than one-third of patients achieved target urate levels within the first year.

Original Source(s)

Serum Urate Goals Tied to Lower CV Risk

  • by Andrea Surnit

  • May 11, 2026

Related Content

Who Decides When a Doctor Steps Back?

Cognitive decline, credentialing, and why “I’ll know” often isn’t enough.

Tendon and Ligament Involvement in Gout With Associated Tendon Rupture

Do Urate Targets Influence CV Risk?

Researchers examine whether achieving treat-to-target serum urate levels with urate-lowering treatment affects long-term cardiovascular outcomes in patients with gout.